IPP Bureau
OneSource Specialty Pharma appoints Jeffrey Wong as CBO
By IPP Bureau - July 08, 2025
He has held senior leadership positions at Syngene International, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations
Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity
By IPP Bureau - July 08, 2025
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Godavari Biorefineries' anti-cancer patent now validated in Spain and UK
By IPP Bureau - July 07, 2025
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Dr. Jitendra Singh inaugurates 'National Biobank' at CSIR-IGIB
By IPP Bureau - July 07, 2025
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
Biocon Biologics receives MHRA UK approval for Vevzuo and Evfraxy, Denosumab Biosimilars
By IPP Bureau - July 07, 2025
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Sigachi Industries appoints Lijo Stephen Chacko as Deputy Group CEO
By IPP Bureau - July 07, 2025
Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries
SPARC incorporates subsidiary ‘Genokine Biotech’
By IPP Bureau - July 07, 2025
The wholly owned subsidiary will carry on the business of all types of research and development and other related services
GACL flags of first dispatch of Benzyl Alcohol and Benzaldehyde
By IPP Bureau - July 06, 2025
The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde
Shilpa Pharma Lifesciences Unit-1 inspected by ANVISA
By IPP Bureau - July 06, 2025
The audit has been concluded with no major observations
Suraksha Diagnostic unveils Eastern India's largest genomics lab
By IPP Bureau - July 06, 2025
Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer
By IPP Bureau - July 06, 2025
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
European Commission fines Alchem for participating in API cartel
By IPP Bureau - July 05, 2025
The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle
Faron publishes study highlighting role of sClever-1 as immune blocker in cancer
By IPP Bureau - July 04, 2025
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
atai and Beckley Psytech announce positive Phase 2b results for treatment-resistant depression
By IPP Bureau - July 04, 2025
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
argenx advances clinical development of agonist antibody for myasthenic syndromes
By IPP Bureau - July 04, 2025
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
